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Two structurally distinct types of CD3-associatedTCR exist . The majority of pe-
ripheralT lymphocytes and a sizeable portion ofthymocytes expressa90-kD disulfide-
linked heterodimer composed ofTCR-a and -/3 glycoprotein subunits (1-3) . TCR
a/a-expressing cells use this receptor to recognize antigens in thecontextofselfMHC
molecules (4) . Recently, two novel rearranging TCR genes and their cell surface
products (termed TCRy/S) have been identified on a small subset of thymic and
peripheral lymphocytes (reviewed in reference 5) . In man, this new TCR occurs
in three structurally distinct forms, depending on the usage of differentTCRy con-
stant region genes (6) . The biological role and repertoire ofTCR'r/S are not fully
defined . While evidence exists that TCR-y/S is part ofa cell surface structure capable
of transducing activation signals resulting in proliferation (7), lymphokine produc-
tion (7), and cell-mediated cytotoxicity (8, 9), the nature of both the antigens and
the restriction elements recognized by thisTCR is still a matter of speculation . De-
spite this enigma, it is likely that TCRy/S+ lymphocytes comprise a newly defined
and separate sublineage of T cells, distinct from TCRa//3+ cells .
In man, TCRy/S was initially identified on Tcell lines that shared twomain pheno-
typic characteristics, namely, lack of reactivity with mAbs against TCRa/(3 and
in most cases a "double-negative" (CD4-8 -) phenotype (7, 10-12) . Using indirect
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analyses, cells bearinga phenotype consistent with that ofcultured TCR-'Y/6-expressing
lymphocytes (CD3+, TCR-a/0-, CD4-8-) have been found in peripheral blood in
proportions ranging between 0.5 and 10% of CD3+ lymphocytes and at even lower
frequencies (0 .2-0.9%) in postnatal thymus (7, 10, 11, 13). However, WT31, the mAb
generally used to demonstrate lack of TCR-a/o expression, does not exclusively stain
TCR-a/(3` lymphocytes; rather, it also weakly reacts with TCR-y/S+ cells (14, and
see below). Moreover the quantitative assessment of TCR-y/6 ` cells based on lack
of CD4 and CD8 expression is not accurate, since the double-negative phenotype
can be associated with either TCR-7/6 or TCR-a/,6 expression and since CD8+
TCR-y/6+ PBL have been described (10, 15, 16, and unpublished observations) . A
precise quantitative evaluation of the TCR-y/6-expressing cell population thus de-
pends on the use of mAbs specifically directed against TCR-y/6. Most of the avail-
able mAbs against TCR-y/b (e.g., anti-NKFI [12], antiTiyA [16], 13133 [17], 6TCS-1
[18]) appear to react with only subsets of TCR-y/6+ cells, while antiTCR-61 (19),
anti-CyMl (6), and antiTCR-y/6-1 (20) may have panreactivity with ally/6 T cells.
To more fully describe the TCR-y/6+ T cell population, we have determined both
quantitative and phenotypic features of this cell system and analyzed its tissue dis-
tribution and microanatomy within individual organs using two mAbs that are specific
for the TCR-y/6 complex and appear to have framework reactivity (antiTCR61 and
anti-C-yMI [6, 19]). As described below such an analysis contributes to understanding
the physiologic potential of TCR-y/6+ lymphocytes in vivo.
Materials and Methods
Tissue Sampling.
￿
Fetal tissue (thymus, spleen, smalland largeintestine, liver, lung, kidney,
and adrenalgland) wasobtained at thetime of postmortem examination from electively aborted
fetuses (n = 9, gestational ages, as determined by crown rump length, menstrual records,
and fetal morphology were 10, 14, 17, 18, 20, and 21 wk). Consent formsandcollecting prac-
tices were approved by the Committee for theProtection of Human Subjects from Research
Risks (Boston, MA). Full-term neonatal (n = 3) and postnatal thymi (n = 18, age range,
6 wk to 6 yr) were obtained from normal children undergoing corrective cardiac surgery.
Adult human peripheral blood was donated by randomly selected healthy volunteers (n =
29, age range 23-54 yr). Specimens ofadulttissue (bone marrow, n = 1; tonsil, n = 9; lymph
node, n = 8; spleen, n = 7; small (duodenum, n = 5; jejunum, n = 2; ileum, n = 6) and
large (colon, n = 5) intestine; liver, n = 5; lung, n = 4; skin, n = 10; kidney, n = 1; brain,
n = 4; heart, n = 1; ovary, n = 1; adrenal gland, n = 1) were obtained from specimens
removed for diagnostic or therapeutic purposes or at the time of autopsy.
mAbs.
￿
mAbs used were anti-Leu-9 (CD7 ; 21), anti-Leu-5b (CD2; 22), anti-Leu-1 (CD5;
23), anti-Leu-6 (CDI; 24), anti-Leu-3a (CD4; 25), OKT4 (CD4; 26), anti-Leu-2a (CD8 ;
25), OKT8 (CD8; 27), anti-Leu-4 (CD3 ; 25), T3b(CD3; 28), 64.1 (CD3 ; 29), WT31 (TCR
a//3 >-y/b; 30), (OF1 (TCR/3; 31), antiTCR61 (TCR-6; 20), anti-C7MI (TCRy; 6), 9.3 (CD28;
32), anti-Leu-11 (CD16; 33), anti-Leu-15 (CD11b; 34), anti-Leu-7 (35), anti-Leu-M3 (CD14;
36), anti-Leu-12 (CD19), anti-HLA-DR (37), and anti-IL-2-R (CD25; 38). Anti-Leu mAbs
were purchased from Becton Dickinson & Co., Mountain View, CA; OKT mAbs were pur-
chased from Ortho Diagnostic Systems Inc., Westwood, MA. AntiTCR-61 and anti-C'YMI
were derived in our laboratory. Isotype-matched control Ig that do not react with human
leukocytes were used as controls.
Immunofluorescence Analysis of Cell Suspensions.
￿
Thymocyte suspensions were prepared by
gently teasingthymic tissue into single cell suspensions using the entire thymic lobule to en-
sure that cortical andmedullary thymocytes were accurately represented. For splenocyte sus-
pensions, spleens were minced to prepare a single cell suspension. Viable mononuclearcells
from thymus, spleen, and peripheral blood were isolated using Ficoll/Hypaque. For single-GROH ET AL.
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color analysis thymocytes/PBMC/splenocytes were resuspended in PBS/1 % FCS/0 .02 070
NaN3 at 2 x 106 cells/ml containing appropriately diluted mAbs and incubated for 30 min
at 4°C. After two washes in PBS/1'7o FCS, antibody binding was visualized by using FITC-
labeled F(ab')2 goat anti-mouse Ig (Tago Inc., Burlingame, CA). Two-color staining was per-
formed using FITC-conjugated mAbs or unconjugated mAbs together with FITC-conjugated
goat anti-mouse Ig and either phycoerythrin (PE)'- or biotin-conjugated mAbs with PE-
conjugated streptavidin (Becton Dickinson & Co.) as the second-step reagent(s). For three-
color immunofluorescence cellswere stained with FITC-, PE-, and biotin-conjugated mAbs
together with APC-conjugated streptavidin (Becton Dickinson & Co.). Labeled cells were
analyzed by a flow cytometer (Ortho Diagnostic Systems Inc.) or FACStar flow cytometer.
Immunohistologic Analysis of Cryostat Sections.
￿
Tissues were snap frozen in liquid nitrogen
with quenching in 2-methylbutane or in cryostats and stored at - 70°C until use. 4-pm serial
cryostat sections were mounted on glass slides, air dried, and stored at -20'C until use.
After 5-min acetone fixation tissue sections were immunostained usinga three-stage biotin-
avidin-peroxidase procedure as previously described (39, 40). Briefly, cryostat sections were
first exposed to normal horse serum (2.5 % in PBS) to inhibit nonspecific binding of horse
Ig, followed by an overnight incubation with the appropriately diluted mAb. The subsequent
step to block endogenous peroxidase activity with H202 was followed by incubation first with
biotin-conjugated horse anti-mouse Ig and second with avidin-biotinylated peroxidase com-
plex (both from Vector Laboratories, Inc., Burlingame, CA). Sections were then subjected
to a 3-amino-9-ethylcarbazole (Aldrich Chemical Co., Milwaukee, WI) reaction. After nu-
clear counterstaining with hematoxylin, sections were mounted in glycergel (Dako; Accurate
Chemical & ScientificCorp., Westbury, NY). In kidney and liver sections endogenous biotin
activity was blocked as previously described (41). In all tissues except gut epithelium and
epidermis, percentages of antiTCR-Sl- and anti-C-yMI-reactive cells within the CD3' cell
population were enumerated by counting all CD3' or TCR-7/6' cells, respectively, in five
high power fields of each section using a calibrated optical grid. In cryostat sections of gut
a 20-mm stretch of epithelium was screened for the relative number of CD3' and TCR-y/b'
cells, respectively. Quantification of intraepidermal TCRy/b' lymphocytes was performed
in immunostained epidermal sheet preparations as previously described (42) .
Results
Reactivity of mAb Anti-MR-61.
￿
mAb antiTCR61 is directed against an epitope
on the TCR-S chain (6, 20). It binds, without exception, to all CD3+ TCRa/o-
T cell clones and polyclonalcell lines examined, including cells bearing TCR-y and
-6 subunits encoded by a variety of TCRy and TCRb V, J, and C region gene
segments (Krangel, M. S., A. Lanzavecchia, T. Hercend, J. Borst, H. Spits, J. E.
de Vries, S. H. Ip, W.J. Tian, personal communications and our unpublished ob-
servations). To further examine the reactivity of antiTCR61, we determined its ability
to bind to CD3+ PBL lacking TCRa/g expression based on their staining behavior
with mAb WT31. As demonstrated earlier (14), WT31 strongly binds to the surface
of TCR-a/o+ cells but weakly stains cultured TCR-y/S+ lymphocytes. Two-color
staining using WT31 (along they-axis) and antiTCRbl (along the x-axis) revealed
two distinct populations (Fig. 1 a) . In addition, note that the profile of antiTCR-
bl' cells shifted slightly away from the x-axis (see arrow, Fig. 1 a), indicating that
all TCR-,y/6' cells also weakly react with WT31. This result was confirmed by
similar two-color cytofluorographic analysis of PBMC with anti-CD3 and WT31,
which revealed two distinct CD3+ populations: one that is weakly reactive with
WT31 (see arrow pointing to cell population shifted to the right of the x-axis in Fig.
' Abbreviation used in this papa: PE, phycoerythrin.1280
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FIGURE 1 .
￿
Two-color cytofluorographic analysis ofTCR-a/a, TCR-y/b, andCD3 expression by
PBL . (A) Staining with both WT31 (y-axis, green staining) and antiTCR-bl (x-axis, red staining)
allows visualization oftwo separate populations : one reactive with WT31 alone (along they-axis)
and a second double stained with both WT31 and antiTCR-b1 . Note that the antiTCR-SI' popu-
lation has shifted away from the baseline of the x-axis (see arrow), indicating that TCR--y/6' cells
weakly react with mAb WT31 . (B) Two-color analysis using anti-CD3 (x-axis, red staining) and
WT31 (y-axis, green staining) reveals that most CD3' PBL unequivocally stain with WT31 and
are clearly double positive (along the diagonal of the grid) . In contrast, a small population of
CD3' PBL are only very weakly reactive with WT31, since their profile (along the x-axis) is shifted
slightly away from the x-axis baseline (see arrow) . (C) All ofthe CD3' PBL that were weakly reac-
tive with WT31 (B) react with antiTCR-b1 . A combination ofWT31 and antiTCR-bl together
stains all CD3' PBL . PBMC were first incubated with WT31 (A and B) orWT31 and antiTCR-
bl (C) followed by FITC goat anti-mouse Ig (y-axis, green staining) . Free binding sites of the
second-step reagent were blocked with normal mouse serum and cells were then incubated with
biotinylated antiTCRbl (A) or biotinylated 64 .1 (anti-CD3) (B and C) followed by PE-streptavidin
(x-axis, red staining) . Using forward angle and side scatter a gate was set to include all lymphocytes.
1 b) and another more strongly stained with WT31 and clearly double positive for
WT31 and CD3 (Fig . 1 b) . Concomitant staining of PBMC with anti-CD3 in red
(x-axis) and with bothWT31 and antiTCR-S1 in green (y-axis) revealed one double-
stained population, indicating that WT31 and antiTCRbl together react with all
detectable CD3+ lymphocytes (Fig . 1 c) . This type of analysis was carried out on
PBL samplesfrom 16 different individuals with similar results, indicating thatWT31
and antiTCR-bl together reacted with all CD3 + cells in peripheral blood . Taken
together, the analysis of individual T cell lines and clones known to use different
TCR-b gene segments and themAb reactivity with all WT31 - or WT31dull cells in
peripheral blood argue strongly that the antiTCR-bl mAb reacts with a framework
determinant present on all TCR-y/b-bearing lymphocytes .
The Number and Phenotype of TCR-y/6' Lymphocytes in Peripheral Blood and Spleen .
The proportion of antiTCRbl' cells ranged between >0.5 and 16.3% (mean, 4.9%)
ofCD3' PBL in 26 of 29 donors studied (Fig. 2) . Serial measurements performed
on some individuals revealed that the percentages of antiTCRb1' PBL remained
nearly constant for each individual overa period ofat least 6mo. In 3 of 29 samples,
antiTCR-b1 reactivity was below the limit of detection by cytofluorography (i.e.,
they contained 50.5% reactive cells) . However, in at least some of these individuals,
TCR-y/b' cells were successfully cloned from peripheral blood, suggesting that even
when undetectable by cytofluorographic staining, TCRy/b-bearing cells appeared
to be present in all individuals .
AntiTCRb1' PBL have been further examined by two- and three-color cytofluoro-
graphic analysis for the expression of other cell surface molecules relevant to T cell
function and differentiation (Table I) . For technical reasons this analysis was per-
formed on PBMC samples obtained from 12 different subjects containing >2 o lo TCRGROH ET AL.
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FIGURE 2.
￿
Numbers of TCRy/S' lymphocytes
in peripheral blood. The number of CD3' PBL
expressingTCR-y/6 wasdetermined by staining
with a specific mAb (antiTCR-S1) and flow
cytometry. Percent antiTCR-61' PBL T cells
were calculated by 100 x (numbers antiTCR-
bl' cells/numbers anti-CD3' cells). Results were
roundedto nearest whole percentile. 29 normal
subjects (23-54 yr ofage) were examined. Each
closed circle represents one individual.
PERCENT ANR-TCRSI + PBL TCELLS
y/S' cells among theirCD3+ PBL. In five of five samples all antiTCR-S1 + PBL were
CD7', CD5', and CD2', although CD5 expression by these cells was about fivefold
less than on TCRc>:/(3' lymphocytes. CD1 was consistently absent from TCR--y/S'
PBL. Although not emphasized previously, in three of seven individuals examined,
-1-4% of the antiTCR-S1' cells expressed CD4 (Fig. 3, a and 6). In contrast, in
seven of seven individuals, a sizable portion (-10-70%) of antiTCR-S1' lympho-
TABLE I
Phenotype of Anti-TCR-S1' Cells in Peripheral Blood of Normal Donors
Percent positive indicates the percent of anti-TCR-61' cells that express the
CD antigen noted. Numbersin parentheses refer to numbers of samples con-
taining anti-TCR-dl' cells of the CD phenotype noted vs. the total number
of individuals analyzed .
' Due to the low amounts of Leu-7 antigen expressed, accurate quantification
was not possible.
h
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= . 0'5 I 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
CD antigen Percent positive
T cell-related antigens
CD7 -100% (5 :5)
CD2 -100°/0 (5:5)
CD5 -100% (5 :5)
CD1 Not detectable (5 :5)
CD4 -1-4% (3 :7)
Not detectable (4:7)
CD8 -10-70% (7 :7)
NK cell-related antigens
CD16 -10% (1 :5)
Not detectable (4:5)
CD11b -50% (5 :5)
Leu 7 (3 :5)
Non-T cell-related antigens
CD14 Not detectable (5 :5)
CD19 Not detectable (5:5)
T cell activation-related antigens
CD25 Not detectable (5:5)
Class 11 Not detectable (5:5)
CD28 -50% (5:5)1282
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FIGURE 3.
￿
Two-colorcytofluorographic analysis ofCD4andCD8 expression by TCR.y/S' PBL.
Contour maps (A and C) show two-channel fluorescence of PBMC gated by forward and side
light scatter for lymphocytes. Asecond gate was set to include all antiTCRSl' cells and 1,000
cells falling within this gate were analyzed forCD4andCD8 expression respectively (B and D).
(A and B) A small but distinct number of antiTCR-S1* cells also reacts with anti-CD4 mAb
(see dots in quadrant 5, A; as well as arrow pointing to small population of gated antiTCR61'
cells reactive with anti-CD4, B). The majority of PBL reactive with anti-CD4 mAb, however,
are unreactive with antiTCRSl and presumably express TCRa//3 (quadrant 4, A). (C and D)
A sizeable number of antiTCRS1' cells also reacts with anti-CD8 (see dots in quadrant 5, C;
as well as theprofilelocated to the rightof vertical marker line representing gated antiTCRS1
cells that also react with anti-CD8, D). The majority of CD8' PBL are unreactive with anti-
TCR61 and presumably express TCR-a//3 (quadrant 4, C). CD8 expression by antiTCR-S1`
cells is slightly weaker than that observed on anti-CD8' antiTCR-S1- PBL. PBMC were first
incubatedwith FITC-OKT4 together with FITC-anti-Leu-3a (A andB) or FITC-OKT8 (C and
D) and second with biotinylated antiTCR-Sl followed by PE-streptavidin.
cytes expressed CD8, however, at lower levels than on TCRa//3+ cells (Fig. 3, c and
d). In one of five subjects, N10% of antiTCRS1' cells coexpressed low levels of
CD16 (Fc-R), and in five of five subjects, CD11b (CR3) waspresent in low amounts
on N50% of antiTCRS1' cells. However, precise cluantitation was difficult due to
the low amounts of CD16 and CD11b antigen expression. The same was true for
the expression of the Leu-7 antigen by some antiTCR6I-reactive lymphocytes in
three of five individuals. Anti-Leu-M3 (CD14, monocyte/macrophage antigen) and
anti-Leu-12 (CD19, B cell antigen) did not stain any peripheral TCR7/S' cells. Fur-
thermore, thesecells didnotexpressthep55 subunit of the human IL-2-R or HLA-DR
while the T cell antigen CD28, which is expressed by virtually all TCRa/a' cellsGROH ET AL.
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and is involved in T cell activation, was expressed on -50% of antiTCR-S1 + cells
in five of five individuals studied.
TCRy/b' splenocytes comprised between >0.5 and 15% of CD3' cells in this
organ and their phenotype was similar to TCR-y/b' PBL.
The Number and Phenotype of 7CR-y/b' Lymphocytes in Thymus.
￿
Immunohistologic
studies on the ontogeny of T cell antigen expression in human thymus suggested
that CD3 expression occurs as early as 10 wk of gestation (43). However, at that
gestational age, the fetal thymus consists of two 1 x 3-mm lobes such that an anal-
ysis of cell suspensions is not possible. The earliest fetal thymic tissue that could
be subjected to cytofluorographic analysis came from a fetus of 14 wk of gestation.
Results from this and several other fetal thymocyte suspensions as well as a total
of 21 newborn and young children's thymi revealed that antiTCR-61' cells consti-
tute >0.5-16% (mean, 3.4%) of CD3' thymocytes in 21 of 29 samples. In 8 of 29
samples we failed to detect antiTCRbl' cells in cytofluorographic analysis (i.e.,
50.5% positive cells). However, in each of these thymi, small numbers of TCR-y/b-
bearingcellscould be unequivocally detected by immunohistologic means usinganti-
TCR-bl . The numbers of antiTCRbl' cells did not correlate with either the pre-
or postnatal age of a given fetus/child from the rangeofages studied. More extensive
studies on fetal tissue, however, are necessary to determine whether, as shown for
the murine thymus (44), human TCR-y/b Tcells aremore abundant earlyin thymic
ontogeny. In contrast to thehomogeneously strong antiTCRb1 staining pattern of
peripheral TCRy/b' lymphocytes, in 16 thymus samples two separate antiTCR-
bl' cell populations were distinguished consisting of dull and brightly stained
subsets. As in peripheral blood, antiTCR-b1 and WT31 together reactedwith virtu-
ally all CD3' thymocytes.
In general, antiTCR-bl' thymocytes were similar in phenotype to their cir-
culating peripheral counterparts as determined by two- and three-color cytofluoro-
graphic analysis of a total of seven samples containing >2% TCR-y/b' thymocytes.
AntiTCR-bl' thymocytes expressed CD7, CD2, and CD5 in amounts comparable
with TCR-a//3' thymocytes. Occasionally (two of seven samples) a subpopulation
of antiTCR-61' cells (N10-20%) was weakly CD8', although in most cases, TCR-
y/b' thymocytes were CD4-8-. In contrast to antiTCRb1' PBL, however, a sizeable
portion (N50%) of each antiTCRbl' thymocyte population analyzed expressed low
levels ofCD1, while CD16, CD11b, Leu-7, and CD28 could not be detected. TCR-
y/b' thymocytes, furthermore, lacked IL-2-R p55 subunit and HLA-DR expres-
sion and were negative for CD14 and CD19.
Immunohistologic Analysis ofTCR-y/8` Lymphocytes.
￿
Immunohistologic screening
of various lymphoid and nonlymphoid organs was performed in order to identify
the organs populated by TCR-y/b' cells and to characterize their specific location
within each tissue. To further assure that antiTCR-bl staining in tissues accurately
reflected the number and location of TCRy/b' lymphocytes, we used an additional
mAb against the TCR-y/b complex, anti-CyMl. This mAb is directed against a
sequence encoded by the TCR-y CI exon that is shared in Cyl and Cy2 gene seg-
ments (6). Immunoprecipitation analysis showed that the mAb reacts with a con-
stant region determinanton both Cyl- and Cy2-encodedTCRy chains, predicting
that anti-C-yMl has framework reactivity (6). It reacts with the TCR-y protein of1284
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cells in tissue sections and is thus useful for immunohistologic analysis. Im-
munolabeling with both mAbs, antiTCR-S1 and anti-C-yMl, gave quantitatively and
qualitatively similar staining results in all tissues examined.
Tissue samples from all fetal thymi analyzed by flow cytometry, one additional
specimen from a 10-wk-old fetus, three neonatal, and 12 young children's thymiwere
analyzed. Cellsreactive with both antiTCR-61 and anti-CyM1 were presentin each
sample (Fig. 4). Numbers of immunohistologically visualized TCRy/b' thymocytes
closely paralleled those obtained by cell surface staining except that a few positive
cellswere found to be present in all thosethymi that gave negative results by cytofluoro-
graphic analysis on thymocyte suspensions. At 10 wk of gestation, while most of
the thymocytes stained CD3', only a small population (ti5%) of fetal thymocytes
reacted with both of the TCR-y/b-specific mAb. Larger tissue sampling, however,
is necessary to study whether TCR-7/6' cells are the first TCR-expressing cells in
ontogeny comparable with the murine system (45). In all tissue specimens studied,
most TCR--y/6' thymocytes were present within the medulla and the cortico-
medullary junction while fewer TCR--y/6' cells were distributed throughout the
cortex (Fig. 4 b).
In postnatal tonsils (Fig. 5) and lymph nodes TCR--y/6' cells were primarily local-
izedwithin interfollicular and paracorticalareas with occasionalpositive cells within
mantle zones and germinal centers of secondary follicles. This distribution corre-
sponds to the location ofTCR-a//3' lymphocytes in these same tissues, assessed by
staining with mAb/3F1 directed against the TCR-/3 chain (31, and data not shown).
In both fetal (14-21 wk) and adult spleen, TCR--y/6' cells were found in the periar-
teriolar lymphocyte sheath. Rare positive cellswere localized within marginal zones
andthe red pulp. At these latter sites in some samples the proportion ofTCRy/b'
to TCRa//3' cells was higher than in T zones. Numbers ofTCR--y/6' lymphocytes
detected in tonsil, lymph node, and spleen were comparable with those observed
in thymus and peripheral blood, accounting for between N1 and 15% ofCD3' cells.
As within all otherlymphoid tissues, in fetal (14-21 wk) and adult small and large
intestine numbers ofTCRy/b' lymphocytes varied considerably between individual
samples ranging from tit-15% oftotal CD3' gut lymphocytes (Fig. 6). In general,
TCRy/b' cells were found at similar frequencies in both compartments of gut-
associated lymphoid tissue, i.e., within epithelium close to the basal membrane and
within the lamina propria. The distribution and numbers of TCR-y/b' lympho-
cytes in Peyer's patches were similar to those found in lymph nodes and tonsils. In
some sections antiTCR-b1, and less frequently anti-CyMI, weakly stained the cyto-
plasmic content oflarge CD3- epithelial cells. This reactivity, however, was inter-
preted as reflecting nonspecificbindingofthese mAbsto crossreactive determinants
present in epithelial cells.
In cryostat sections ofnormal adult skin from variousbody areas, we foundTCR-
y/b' cells both intraepidermally irregularly scattered within the basal keratinocyte
layer as well as in the dermis (Fig. 7). These cells were rare, but were detectable
in each skin biopsy analyzed. In clinically normal skin, T lymphocytes, mainly of
theTCRy/(3 type, constitutediscrete perivascular infiltrates within the dermis and
occur in rare irregular clusters, interspersed between the most basal keratinocyte
layers, predominantly along the rete ridges (46, Foster, C. A., H. Yokozeki, F. Koning,
et al., manuscript inpreparation and ourunpublished observation)(Fig. 7 a). TheirGROH ET AL .
FIGURE 4 .
￿
Immunohistologic visualization of TCR--y/b' thymocytes . Serial cryostat sections of
normal postnatalthymus were stained by a biotin-avidin-peroxidase procedure using anti-Leu-4
(a) and antiTCR-bl (b) as first-step mAb . (a) The majority of both cortical (C) and medullary
(M) thymocytes stain with anti-Leu-4. (b) AntiTCR-bl-reactive cells are scattered throughout
the tissue . These cells aremore frequent within the medulla(M) and cortico-medullaryjunction
(CMJ) than within the cortex (C) . In the photomicrographs, the arrow points to capsule oflobe
and H identifies a Hassall's body within the medulla.
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FIGURE 5 .
￿
Immunohistologic visualization ofTCR ,y/S' lymphocytes in tonsil . Serial cryostat
sections oftonsil were stained by a biotin-avidin-peroxidase procedure using anti-Leu-4 (a)and
antiTCRS1 (6) as first-step mAb . (a) Numerous anti-Leu-4' cells constitute the interfollicular
(IF) T cell area, while a smaller but substantial number of anti-Leu-4' cells is also present within
germinal centers (GC) andmantle zones(MZ) of secondary follicles (B cell area). (6) AntiTCR-
Sl' cells are localized mainly in the interfollicular area (IF), while a few TCR-y/S' cells are
present within mantel zone (MZ) and germinal center (GC) of a secondary follicle .GROH ET AL . 1287
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FIGURE 7 .
￿
Immunohistologic visualization ofTCRy/b+ lymphocytes in skin. Cryostat sections
of normal skin were stained by a biotin-avidin-peroxidase procedure using anti-Leu-4 (a) and
antiTCRbl (b and c) as first-step mAb . (a) Intraepidermal anti-Leu-4' cells (arrows) are inter-
spersed between basal keratinocytes in the epidermis (E), some anti-Leu-4' cells are also scat-
tered throughout the upper dermis (D) . (b)One single intraepidermal antiTCR-bl* cell (arrow)
is located within the most basal keratinocyte layer of the epidermis (E). In another section anti-
TCR-bl' cells are noted within the basal epidermis (E) (arrows) and the dermis (D). (a-c) In
normal skin T lymphocytes are not evenly distributed throughout Eand D, rather they form
clusters at both these sites . Therefore, in order to immunohistologically demonstrate the pres-
ence ofT cells within skin, numerous serial sections of each skin specimen were screened to ob-
tain the examples shown . The majority of skin sections contained no lymphocytes .GROH ET AL.
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irregular intraepidermal distribution patterncanbe examined reliably onlyin whole
epidermal mounts. Therefore, we analyzed epidermal sheets, which showed that
TCR-y/S+ cells comprise between ti1 and 15% of CD3' lymphocytes within the
basal epidermis. Thus, the relative proportion ofintraepidermal CD3+ lymphocytes
that were TCRy/S' was comparable with the other lymphoid tissues. The same was
true for perivascular TCR--y/6' cells.
TCR--y/6' lymphocytes in all tissues harboring these cells did not occur in large
clusters and were observed only rarely in small groups oftwo to five cells. Instead,
TCR--y/6' lymphocytes appeared to be dispersed as single cells in the respective
tissue. In the few samples offetal (14-21 wk) and adult lung analyzed, we were un-
able to detect TCRy/S+ cells. More extensive studies are therefore needed to
reliably determine the presence or absence ofTCRy/S' lymphocytes in bronchus-
associated lymphoid tissue. None ofthe nonlymphoid fetal or adult tissues exam-
ined showed staining with either antiTCR61 or anti-CyMl. We occasionally ob-
served one or two TCR--y/6' lymphocytes in very close proximity ofor even within
blood vessels in several organs, reflecting the ability ofthese cells to circulate.
Discussion
Using twospecific mAbs, antiTCRS1 and anti-CyMl we carried out a direct anal-
ysis of TCR--y/6' cells in man. AntiTCRS1 stained all WT31 - or WT31d°° lym-
phocytes, indicating that all CD3+ TCRa/f - cells in adult peripheral blood and
in fetal as well as postnatal thymus express a TCRS chain. This staining of all
WT31 - or WT31d°" CD3' cells taken together with other data, suggests that anti-
TCR-61 and anti-CyMl recognize TCR-y/S determinants shared by all y/STcells.
Based on antiTCRS1 reactivity inperipheral blood, thymus, andlymphoid tissue,
we conclude that y/S Tcells range between >0.5 and 16% (mean, -4%) ofCD3+
cells in a panel of individuals. Given the variation of TCRy/S+ T lymphocyte
counts in individuals, severallymphoid tissues (thymus, spleen, intestine, and liver)
were available from the same fetuses in eight ofnine cases and simultaneous quan-
titative analysis of TCR-7/6' cells indicated that the relative percentage of TCR-
y/S' cells populating these organs was consistent for a given fetus. The presence
of 10-1617o of the Tcells as TCR-,y/6' cells was occasionally found for a particular
donor. Whether high TCR--y/6' lymphocyte proportions in some individuals with
anotherwisenormal distributionofhaemopoietic cell populations reflect individual
variations within a quantitatively normal resting range, or rather, indicate a state
of activation of this cell pool, remains to be determined.
TCR-y/S-bearing lymphocytes have been generally referred to as double nega-
tives. Although a sizeable portion ofy/S T cells do lack CD4 and CD8 expression,
nearly halfexpress CD8 (however at lower levels than TCRa/0+ lymphocytes) and
a very small portion express CD4. Other markers ofdifferentiation and activation
that are foundona//3 Tcellsalso occur on TCRy/&-bearing cellsalthough notalways
at similarfrequencies (Table I). Thus, they/S Tcell population appears tobepheno-
typically diverse and may therefore itself be composed of several subsets.
AntiTCR-S1 and anti-CyM1 mAbs also made it possible to analyze the tissue
distribution and microanatomical location ofthese cells. TCRy/S+ cells regularly
populate all lymphoid tissues and were usually present as N1-15% ofthe total CD3'
cells. In organizedperipherallymphoidtissues (tonsils, lymph nodes, Peyer'spatches,1290
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and spleen), TCR--y/6' cells were scattered throughout the classical T cell areas and
thus, in general, paralleled the microanatomical location ofTCR-a/0' lymphocytes,
however, at lower densities. Some TCR--y/6' cells were present in B cell areas of
lymph follicles as well as within marginal zones and red pulp in spleen. At these
two latter sites, in some specimens the proportion ofTCRy/S' to TCR-a/o' cells
appeared higher than within T zones in general. This pattern raises the possibility
of a site-specific role for TCR-7/6 in such predominantly B cell areas and in the
red pulp of the spleen.
The vastmajority ofmurine intraepithelial gutlymphocytes appear to bearTCR-
y/S (47). Within the avian intestine, TCR--y/6' lymphocytes predominantly localize
to the gut epithelium (48). This abundant presence of TCRy/S' cells in surface
epithelia has fostered speculations that these cells may recognize a specific set of
antigens prevalently entering the organism via the gut ormight have specific effector
functions closely related to this particular microenvironment (49). In man, in addi-
tion to Peyer's patches, the gut-associated lymphoid tissue consists of CD3' lym-
phocytes located within the epithelium and the subepithelial connective tissue (39).
In human gut we found TCR-7/6' lymphocytes at both these locations accounting
for -1-150 /c ofthe total CD3* cell population. Thus, unlike the results in mouse,
in none ofthe human samples analyzed in this study were TCRy/S' gut-associated
lymphocytes found to comprise more than ti157o of total CD3' lymphocytes. Fur-
thermore, these cells did not preferentially populate the gut epithelium, but they
were present in both the epithelium and within the lamina propria. Thus, while
TCR--y/6' cells are present as part ofthe human gut-associated lymphoid system,
these results differ both quantitatively and qualitatively from that reported formice
and chicken (47, 48). It remains to be determined whether the biological role of
murine and avian TCRy/S' intraepithelial gut lymphocytes in man is provided by
a specific subset of TCR-a/0' cells or rather is adequately fulfilled by the more
limited number of TCR--y/6' gut lymphocytes found in man.
Murine CD3' epidermal lymphocytes are highly dendritic, located at a supra-
basal position, and most, ifnot all of them, express TCR-y/S (50). In man, normal
skin is regularly populated by small numbers oflymphocytes (46, Foster, C. A., H.
Yokozeki, F. Koning, et al., manuscript in preparation and our unpublished obser-
vation). Within the epidermis these cells are scattered throughout the most basal
keratinocyte layers, inthe dermis they mainly hometo perivascular areas. This study
shows that -1-150 /c of both these intraepidermal and dermal CD3' lymphocytes
expressedTCR-y/S. Based on immunohistologic studiesofepidermal sheet prepara-
tions, preliminary evidence exists that in the human epidermis, in addition to in-
traepidermal basally located TCR--y/6' lymphocytes, dendritic suprabasal CD1',
HLA-DR', Fc-R', CD4' epidermal cells (presumably Langerhans cells) display
weak anti-CD3/TCRy/Sreactivity (V. Groh, unpublished observation). It remains
to be determined whether these staining results indeed reflect CD3/TCRy/S ex-
pression bythesecells, which according to presentknowledge, are thoughtto belong
to the monocyte/macrophagelineage (51). However, both theirmicroanatomy within
the skin as well as their phenotype and function would still differ from their putative
murine counterpart. Thus, at present, compared with the situation in mice, it is
less clear that a prevalent tropism of TCRy/8' cells for human epithelia occurs.
Taken together, it appears that human TCRy/S' cells are present in similarGROH ET AL.
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proportions throughout virtually all lymphoid organs, and in general, tend to be
located within each organ wherever TCRa/0' lymphocytes are found.
Rather than existing only as a precursor population ofTCR-a//3+ lymphocytes,
the results presented in this studyand dataemerging regarding theeffector capabili-
ties ofthese cells (52) suggest that TCR--y/6' cells constitute a distinct mature sub-
population ofT cells distributed along with TCR-a/a+ cells throughout the human
lymphoid system. While the possibility ofa special role for TCR--y/b + cells in epi-
thelial organs in man must be considered, it seems likely that these cells utilize their
distinct TCR and possibly distinct antigen-presenting molecules to broaden the T
cell repertoire. As the current study shows they may do this as a phenotypically di-
verse population ofT cells able to participate in immune responses at virtually all
immunologically relevant sites within the human organism.
Summary
A direct quantitative and phenotypic cytofluorographic analysis of TCR-y/b+
lymphocytes as well as an immunohistologic study of their tissue distribution and
microanatomy was made possible by the availability oftwomAbs (antiTCR-bl and
anti-CyMl) specific for framework determinants on human TCR y and b chains,
respectively. TCRy/b+ lymphocytes, ranging between >0.5 and 16° /% ofCD3+ cells,
were found in fetal andpostnatal thymus, fetal and adult peripherallymphoidorgans,
and adult peripheral blood. While TCR-,y/6' lymphocytes comprised a small sub-
population of T cells (mean, ti4%) occasionally >10-16% ofCD3+ cells expressed
TCRy/b. Virtually all TCR-,y/6' thymocytes/lymphocytes expressed CD7, CD2,
and CD5 but were heterogeneous with respect to their expression of CD1, CD4,
CD8, CD28, CD11b, CD16, and Leu-7. Human TCR-y/b+ cells populate both or-
ganized lymphoid tissues (thymus, tonsil, lymphnode, and spleen) as well as the
gut- and skin-associated lymphoid systems at similar frequencies without obvious
tropism forepithelial microenvironments. TCRy/b+ lymphocytes tend to be located
within a given organ wherever TCRa/o+ lymphocytes are found. This study shows
that TCR-,y/6' lymphocytes constitute a small but numerically important, pheno-
typically diverse T cell population distributed throughout the body. These results
support the concept that TCR-y/b+ cells comprise a distinct, functionally hetero-
geneous, mature T cell sublineage that may substantially broaden the T cell reper-
toire at all immunologically relevant sites.
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